UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2012
Commission File Number: 001-34564
China Nuokang Bio-Pharmaceutical Inc.
No. 18-1 East Nanping Road
Hunnan National New & High-tech Development Zone
Shenyang, Liaoning Province
People’s Republic of China 110171
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| China Nuokang Bio-Pharmaceutical Inc. |
| |
| By: | | /s/ Baizhong Xue |
| Name: | | Baizhong Xue |
| Title: | | Chairman and Chief Executive Officer |
Date: September 28, 2012
Exhibit Index
| | |
Exhibit No. | | Description |
| |
Exhibit 99.1 | | Press Release |
| |
Exhibit 99.2 | | Agreement and Plan of Merger by and among Kingbird Investment Inc., Kingbird Mergerco. Inc., China Nuokang Bio-Pharmaceutical Inc. and certain other parties thereto dated as of September 27, 2012 |
